Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRDL OTCMKTS:CYAN NASDAQ:REVB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRDLCardiol Therapeutics$1.16+3.1%$1.33$0.88▼$1.71$133.11M0.72546,683 shs331,671 shsCYANCyanotech$0.44$0.39$0.21▼$0.57$3.25M0.15671 shsN/AREVBRevelation Biosciences$1.03-1.0%$1.12$0.88▼$12.88$4.03M-0.09409,924 shs18,251 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRDLCardiol Therapeutics-2.61%-12.50%-18.25%+12.00%-14.50%CYANCyanotech0.00%-15.37%+13.08%+2.33%+8.00%REVBRevelation Biosciences-1.89%-4.59%-7.14%-16.13%-90.38%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRDLCardiol Therapeutics$1.16+3.1%$1.33$0.88▼$1.71$133.11M0.72546,683 shs331,671 shsCYANCyanotech$0.44$0.39$0.21▼$0.57$3.25M0.15671 shsN/AREVBRevelation Biosciences$1.03-1.0%$1.12$0.88▼$12.88$4.03M-0.09409,924 shs18,251 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRDLCardiol Therapeutics-2.61%-12.50%-18.25%+12.00%-14.50%CYANCyanotech0.00%-15.37%+13.08%+2.33%+8.00%REVBRevelation Biosciences-1.89%-4.59%-7.14%-16.13%-90.38%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRDLCardiol Therapeutics 2.33Hold$8.50635.93% UpsideCYANCyanotech 0.00N/AN/AN/AREVBRevelation Biosciences 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest PHE, REVB, CYAN, and CRDL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2026REVBRevelation Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)5/13/2026REVBRevelation Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)4/27/2026REVBRevelation Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)4/6/2026CRDLCardiol Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.00(Data available from 6/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRDLCardiol TherapeuticsN/AN/AN/AN/A$0.11 per shareN/ACYANCyanotech$24.22M0.13N/AN/A$1.23 per share0.36REVBRevelation BiosciencesN/AN/AN/AN/A$1.28 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRDLCardiol Therapeutics-$24.20M-$0.28N/AN/AN/AN/A-229.43%-165.60%8/13/2026 (Estimated)CYANCyanotech-$3.20M-$0.25N/AN/AN/A-7.03%-20.62%-7.52%N/AREVBRevelation Biosciences-$8.91M-$39.48N/AN/AN/AN/A-107.65%-87.98%8/7/2026 (Estimated)Latest PHE, REVB, CYAN, and CRDL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026CRDLCardiol Therapeutics-$0.07-$0.07N/A-$0.07N/AN/A5/7/2026Q1 2026REVBRevelation Biosciences-$1.15-$2.71-$1.56-$2.71N/AN/A3/30/2026Q4 2025CRDLCardiol Therapeutics-$0.09-$0.05+$0.04-$0.05N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCRDLCardiol TherapeuticsN/AN/AN/AN/AN/ACYANCyanotechN/AN/AN/AN/AN/AREVBRevelation BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRDLCardiol TherapeuticsN/A4.394.39CYANCyanotech0.121.000.30REVBRevelation BiosciencesN/A10.0210.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRDLCardiol Therapeutics12.49%CYANCyanotech24.40%REVBRevelation Biosciences12.80%Insider OwnershipCompanyInsider OwnershipCRDLCardiol Therapeutics5.25%CYANCyanotech34.40%REVBRevelation Biosciences4.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRDLCardiol Therapeutics20115.25 million109.20 millionNot OptionableCYANCyanotech957.39 million4.85 millionNot OptionableREVBRevelation Biosciences103.91 million3.72 millionNot OptionablePHE, REVB, CYAN, and CRDL HeadlinesRecent News About These CompaniesRevelation Biosciences Expands Acute Kidney Injury Advisory BoardJune 1 at 9:00 AM | accessnewswire.comARevelation Biosciences, Inc. Releases Corporate Update Letter to StockholdersMay 11, 2026 | accessnewswire.comAREVB Poised for Big YearMay 8, 2026 | finance.yahoo.comRevelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026May 7, 2026 | accessnewswire.comARevelation Biosciences Announces Formation of Acute Kidney Injury Advisory BoardApril 6, 2026 | accessnewswire.comARevelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical StudyMarch 30, 2026 | oklahoman.comORevelation Biosciences (REVB) price target decreased by 37.65% to 54.06March 28, 2026 | msn.comREMINDER: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth ConferenceMarch 24, 2026 | accessnewswire.comARevelation Biosciences to Host Fireside Chat at 38th Annual Roth ConferenceMarch 19, 2026 | accessnewswire.comARevelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025February 26, 2026 | accessnewswire.comARevelation Biosciences (REVB) price target increased by 300.00% to 86.70February 4, 2026 | msn.comREVB Comes to Agreement with FDAJanuary 29, 2026 | finance.yahoo.comREVB stock drops 10% after company announces third reverse split in a yearJanuary 26, 2026 | msn.comRevelation Biosciences Inc. Announces 1-for-4 Reverse Stock Split Effective January 28, 2026January 26, 2026 | accessnewswire.comARevelation Biosciences Inc. Announces Exercise of Warrants for $11 Million in Gross ProceedsJanuary 23, 2026 | accessnewswire.comARevelation Biosciences Reaches Agreement with FDA on Gemini Approval Pathway for AKIJanuary 21, 2026 | accessnewswire.comARevelation Biosciences, Inc.: Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care NephrologyJanuary 14, 2026 | finanznachrichten.deRevelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026)January 14, 2026 | accessnewswire.comARevelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)January 12, 2026 | accessnewswire.comARevelation Biosciences, Inc.: Revelation Biosciences Announces Initiation of GMP Manufacturing of GEMINI and Placebo to Support Later Stage Clinical DevelopmentJanuary 8, 2026 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 2026Apple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 2026IonQ Just Posted a Breakout Quarter—But 1 Problem RemainsBy Nathan Reiff | May 7, 2026Before the Moon Base Gets Built, These 4 Companies WinBy Thomas Hughes | May 11, 2026Palomar’s High-Risk Insurance Strategy Is Paying Off BigBy Peter Frank | May 29, 2026PHE, REVB, CYAN, and CRDL Company DescriptionsCardiol Therapeutics NASDAQ:CRDL$1.16 +0.04 (+3.13%) As of 12:53 PM Eastern This is a fair market value price provided by Massive. Learn more.Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.Cyanotech OTCMKTS:CYAN$0.44 0.00 (0.00%) As of 06/2/2026Cyanotech Corp. engages in the cultivation, production, and sale of natural products derived from microalgae for the health and human nutrition markets worldwide. Its products include BioAstin Hawaiian Astaxanthin, a dietary antioxidant, which is used as a human dietary supplement and dietary ingredient to support and maintain the body's natural inflammatory response, enhance skin, and support eye, joint, and immune health; and Hawaiian Spirulina Pacifica, a nutrient-rich dietary supplement that is used for extra energy, a strengthened immune system, cardiovascular benefits, and as a source of antioxidant carotenoids. The company was founded by Gerald R. Cysewski in 1983 and is headquartered in Kailua-Kona, HI.Revelation Biosciences NASDAQ:REVB$1.03 -0.01 (-0.96%) As of 12:52 PM Eastern This is a fair market value price provided by Massive. Learn more.Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas From Runway to Riches: Victoria's Secret's New Look Coke's $10B India IPO Plan Pops the Top on Hidden Value Dell's AI Toll Bridge Is Paved with Record Margins The Blue Origin Explosion Is a Setback for Amazon, Not a Dealbreaker Ulta's Q1 Report Primes It for a Beauty of a Rebound Palo Alto Networks Accelerates Growth 31% on AI Demand How the Memory Shortage Is Crushing the Gaming Industry As AI Data Breaches Become More Common, This Cybersecurity ETF Is Surging Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
